Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review

References

• Neumann PJ, Russell LB, Siegel JE, et al. Using cost-effectiveness in health and medicine: experiences since the original panel. In: Neumann PJ, Sanders GD, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 2017. p. 1–38.
   Google Scholar
• Nohynek H, Wichmann O, D’Ancona F, et al. National advisory groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19:1096–1105.
   PubMed Web of Science ®Google Scholar
• Leidner, AJ, Chesson HW, Meltzer MI, Messonier ML, Lee GM, et al. National Center for Immunization and Respiratory Diseases (NCIRD). Guidance for health economics studies present to the advisory committee on immunization practices (ACIP). 2019 Oct 11; Update https://www.cdc.gov/vaccines/acip/committee/downloads/Economics-Guidance-for-ACIP-2019.pdf. cited 2020 Jun 3
   Google Scholar
• Stone PW, Chapman RH, Sandberg EA, et al. Measuring costs in cost-utility analyses: variations in the literature. Int J Technol Assess Health Care. 2000;16(1):111–124.
   PubMed Web of Science ®Google Scholar
• Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765–778.
   PubMed Web of Science ®Google Scholar
• Krol M, Papenburg J, Tan SS, et al. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. Eur J Health Econ. 2016;17(4):391–402.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. PharmacoEconomics. 2016;34(3):227–244.
   PubMed Web of Science ®Google Scholar
• Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32(4):335–344.
   PubMed Web of Science ®Google Scholar
• Kigozi J, Jowett S, Lewis M, et al. Estimating productivity costs using the friction cost approach in practice: a systematic review. Eur J Health Econ. 2016;17(1):31–44.
   PubMed Web of Science ®Google Scholar
• Sussman M, Benner J, Neumann P, et al. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38(10):1644–1657.
   PubMed Web of Science ®Google Scholar
• Kilian R, Frasch K, Steinert T, et al. Cost-effectiveness of psychotropic polypharmacy in routine schizophrenia care. Results of the ELAN prospective observational trial. Neurol Psychiatry Brain Res. 2018;30:47–55.
   Google Scholar
• Delea TE, Amdahl J, Chit A, et al. Cost-effectiveness of lapatinib plus letrozole in HER2-positive, hormone receptor-positive metastatic breast cancer in Canada. Current Oncol. 2013;20(5):e371–87.
   PubMed Web of Science ®Google Scholar
• Riewpaiboon A. Measurement of costs for health economic evaluation. J Med Assoc Thai. 2014;97(Suppl 5):S17–26.
   PubMedGoogle Scholar
• Zhang W, Sun H, Woodcock S, et al. Valuing productivity loss due to absenteeism: firm-level evidence from a Canadian linked employer-employee survey. Health Econ Rev. 2017;7(1):3.
   PubMedGoogle Scholar
• Krol M, Papenburg J, Koopmanschap M, et al. Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics. 2011;29(7):601–619.
   PubMed Web of Science ®Google Scholar
• Johannesson M, Jonsson B, Jönsson L, et al. Why should economic evaluations of medical innovations have a societal perspective? Office of Health Economics. Briefing. 2009;51:1-32.
   Google Scholar
• Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–359.
   PubMed Web of Science ®Google Scholar
• Tai BB, Bae YH, Le QA. A systematic review of health economic evaluation studies using the patient’s perspective. Value Health. 2016;19(6):903–908.
   PubMed Web of Science ®Google Scholar
• Yuasa A, Yonemoto M, LoPresti M, et al. Use of productivity loss/gain in cost-effectiveness analyses for drugs: a systematic review. Pharmacoeconomics. 2020;39:81–97. Available ahead of print.
   PubMed Web of Science ®Google Scholar
• Haute Autorité de santé (HAS). Choices in methods for economic evaluation: a methodological guide. Department of Economics and Public Health Assessment, HAS, Saint-Denis La Plaine, France. 2012. cited 2020 Jun 3. https://www.has-sante.fr/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf
   Google Scholar
• Center for Outcomes Research and Economic Evaluation for Health. Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council (version 2.0). National Institute of Public Health (C2H), Japan, Tokyo. cited 2020 Jun 3. https://c2h.niph.go.jp/tools/guideline/guideline_en.pdf
   Google Scholar
• The Robert Koch Institute. Modelling methods for predicting epidemiological and health economic effects of vaccinations – guidance for analyses to be presented to the German standing committee on vaccination (STIKO). Version 1.0; Mar 2016.
   Google Scholar
• Centre for Reviews and Dissemination (CRD). University of York. Systematic reviews: CRD’s guidance for undertaking reviews in health care. York, UK: Centre for Reviews and Dissemination (CRD), University of York; 2009.
   Google Scholar
• Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.0. Cochrane, London, UK; Jul 2019. cited 2020 Jun 3. https://training.cochrane.org/handbook
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Sakamaki H, Ishida H, Fukuda T, et al. Issues on estimating costs in economic evaluation [in Japanese]. Jpn J Pharmacoepidemiol. 2012;17(1):14–20.
   Google Scholar
• The World Bank Group, World Bank country and lending groups. cited 2020 Mar 18. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.
   PubMed Web of Science ®Google Scholar
• Hettiarachchi RM, Kularatna S, Downes MJ, et al. The cost-effectiveness of oral health interventions: a systematic review of cost-utility analyses. Community Dent Oral Epidemiol. 2018;46(2):118–124.
   PubMed Web of Science ®Google Scholar
• Palfreyman SJ, Stone PW. A systematic review of economic evaluations assessing interventions aimed at preventing or treating pressure ulcers. Int J Nurs Stud. 2015;52(3):769–788.
   PubMed Web of Science ®Google Scholar
• Rogers HJ, Rodd HD, Vermaire JH, et al. A systematic review of the quality and scope of economic evaluations in child oral health research. BMC Oral Health. 2019;19(1):132.
   PubMedGoogle Scholar
• Hope SF, Webster J, Trieu K, et al. A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS One. 2017;12(3):e0173600.
   PubMed Web of Science ®Google Scholar
• D’Angiolella LS, Lafranconi A, Cortesi PA, et al. Costs and effectiveness of influenza vaccination: a systematic review. Ann dell’Istituto Super Sanità. 2018;54(1):49–57.
   PubMed Web of Science ®Google Scholar
• Seto K, Marra F, Raymakers A, et al. The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs. 2012;72(5):715–743.
   PubMed Web of Science ®Google Scholar
• Loze PM, Nasciben LB, Sartori AMC, et al. Vaccines are different: a systematic review of budget impact analyses of vaccines. Vaccine. 2017;35(21):2781–2793.
   PubMed Web of Science ®Google Scholar
• Leidner AJ, Murthy N, Chesson HW, et al. Cost-effectiveness of adult vaccinations: a systematic review 2019. . Vaccine. 2019;37(2):226–234.
   PubMed Web of Science ®Google Scholar
• Ozawa S, Mirelman A, Stack ML, et al. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine. 2012;31(1):96–108.
   PubMed Web of Science ®Google Scholar
• Neumann P, Cohen JT, Kim DD, et al. Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic. Health Affairs. 2021;40(1):53–61. (fast track ahead of print article).
   Web of Science ®Google Scholar
• Schwartz K, Freed M, Cubanski J, et al. Vaccine coverage, pricing, and reimbursement in the U.S. Kaiser family foundation. Issue Brief. 2020. https://www.kff.org/coronavirus-covid-19/issue-brief/vaccine-coverage-pricing-and-reimbursement-in-the-u-s/ cited 2020 Jun 3
   Google Scholar